Fate Therapeutics remains a high-risk, high-reward biotech play, with recent developments mainly centred around its cell therapy pipeline, particularly FT819 (off-the-shelf CAR-T) for autoimmune diseases.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.